Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia

Leukemia
D SchmidA Gaiger

Abstract

We examined the presence of WT1-specific mRNA in bone marrow samples of 125 patients with de novo acute myeloid leukemia at diagnosis by two-step RT-PCR. The sensitivity of the assay was 1:100 (first step) and 1:10000 (second step), respectively. WT1-specific mRNA was detected in 73% of patients. No correlation was found between WT1 gene expression and age, FAB type, LDH and karyotype at diagnosis. All patients were treated with standard induction chemotherapy. There was no difference in the CR rate between WT1-positive and -negative patients. Using Kaplan and Meier plot analysis we found no difference in disease-free survival (DFS) and overall survival (OS) between patients displaying the WT1 transcript and WT1-negative patients. Furthermore, no significant interactions between WT1 PCR results and age, FAB type, LDH and karyotype on DFS and OS were demonstrable using Cox regression analysis. Eight patients who were WT1 PCR positive at diagnosis and achieved complete hematological remission following chemotherapy were monitored during the course of the disease. Based on our limited data demonstrating a heterogeneity of WT1 PCR results in CR we cannot draw any conclusions regarding the usefulness of WT1 PCR analysis for the earl...Continue Reading

Citations

May 20, 1999·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M LittleP Walsh
May 25, 2001·International Journal of Hematology·Z Chen
Sep 7, 2002·International Journal of Hematology·Hans D MenssenEckhard Thiel
Jul 5, 2003·Experimental Hematology·Imad A Tabbara, Richard M Ingram
Aug 31, 2002·Journal of Hematotherapy & Stem Cell Research·Elizabeth Algar
Sep 7, 2007·Pathology International·Takashi IwasakiTakashi Murate
Sep 24, 2004·The Tohoku Journal of Experimental Medicine·Yasuo TohmiyaTakeshi Sasaki
Nov 1, 2012·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·Charlotta AnderssonAihong Li
Sep 25, 2010·Pediatric Hematology and Oncology·Shao-Yan HuChien-Shing Chen
Jun 30, 2004·Leukemia & Lymphoma·Hiroyasu OgawaHiroya Tamaki
Nov 9, 2001·Leukemia & Lymphoma·M Yasukawa
Oct 7, 2009·Expert Review of Vaccines·Michael SchmittAnita Schmitt
Jun 23, 2011·Expert Review of Vaccines·R Casalegno-GarduñoM Schmitt
Feb 14, 2014·Expert Opinion on Investigational Drugs·Lindsay A M Rein, Nelson J Chao
May 10, 2015·Pharmacology & Therapeutics·Kristen M Meldi, Maria E Figueroa
Apr 9, 2008·Hematology/oncology Clinics of North America·James M Allan
Feb 14, 2004·European Journal of Haematology·S GalimbertiM Petrini
Oct 3, 2007·Genes, Chromosomes & Cancer·Derek L StirewaltJerald P Radich
Dec 18, 2007·European Journal of Haematology·Mauri M HämäläinenTarja-Terttu Pelliniemi
Aug 3, 2006·Pediatric Blood & Cancer·Patricia C RodriguesJosé A Yunes
Dec 17, 2009·Hematological Oncology·Carolyn OwenPeter Paschka

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.